Sun Communities, Inc. Announces Date for First Quarter 2025 Earnings Release and Conference Call
Southfield, MI, April 21, 2025 (GLOBE NEWSWIRE) -- Sun Communities, Inc. (NYSE: SUI) (the 'Company'), a real estate investment trust ("REIT") that owns and operates, or has an interest in, manufactured housing ('MH') and recreational vehicle ('RV') communities and marinas, announces it will release first quarter 2025 operating results after the market closes on Monday, May 5, 2025. The Company will host a conference call to discuss these results on Tuesday, May 6, 2025, at 11:00 A.M. ET.
To Participate in the Conference Call:
Dial at least 5 minutes prior to start time.U.S. and Canada: (877) 407-9039International: (201) 689-8470
The conference call will also be available live on the Company's website www.suninc.com.
Conference Call Replay:
U.S. and Canada: (844) 512-2921International: (412) 317-6671Passcode: 13752708The replay will be accessible through May 20, 2025.
About Sun Communities, Inc.
Sun Communities, Inc. is a REIT that, as of December 31, 2024, owned, operated, or had an interest in a portfolio of 645 developed properties comprising approximately 176,390 developed sites and approximately 48,760 wet slips and dry storage spaces in the United States, Canada, and the United Kingdom.
For Further Information at the Company:
Fernando Castro-CaratiniChief Financial Officer(248) 208-2500www.suninc.comSign in to access your portfolio
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
Brunswick Exploration Announces AGM Results
MONTREAL, June 12, 2025 (GLOBE NEWSWIRE) -- Brunswick Exploration Inc. ('BRW' or the 'Corporation') is pleased to announce the results of its annual general meeting ('AGM') of shareholders held on June 12, 2025. Shareholders holding a total of 80,309,202 common shares of the Corporation attended the AGM in person or were represented by proxy, representing approximately 37 % of the 218,274,932 common shares issued and outstanding. Pierre Colas, Jeffrey Hussey, André Le Bel, Amy Satov, Mathieu Savard and Robert Wares were re-elected to the board of directors. The shareholders also (i) approved the re-appointed Raymond Chabot Grant Thornton LLP as auditors for the ensuing financial year, (ii) approved the deferred share unit plan (the 'DSU Plan') adopted by the Corporation's board of directors on April 30, 2025, allowing for a maximum of 2,400,000 common shares to be awarded as deferred share units under the DSU Plan, and (iii) ratified, approved and confirmed the stock option plan, as amended by the Corporation's board of directors on April 30, 2025, allowing for a maximum of 19,400,000 common shares to be subject to stock options under the stock option plan. Collectively, the number of common shares reserved for issuance under all the Corporation's security-based compensation plans, namely the stock option plan and the DSU Plan, represents less than 10% of the Corporation's currently issued and outstanding common shares. The adoption of the DSU Plan and the amendment to the stock option plan remain subject to final approval by the TSX Venture Exchange. About Brunswick Exploration Brunswick Exploration is a Montreal-based mineral exploration company focused on grassroots exploration for lithium in Canada, a critical metal necessary to global decarbonization and energy transition. The Corporation is rapidly advancing the most extensive grassroots lithium property portfolio in Canada and Greenland. Investor Relations/information Mr. Killian Charles, President and Chief Executive Officer (info@ Cautionary Statement on Forward-Looking Information This news release contains 'forward-looking information' within the meaning of applicable Canadian securities legislation based on expectations, estimates and projections as at the date of this news release. Forward-looking information involves risks, uncertainties and other factors that could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. Factors that could cause actual results to differ materially from such forward-looking information include, but are not limited to, delays in obtaining or failures to obtain required governmental, environmental or other project approvals; uncertainties relating to the availability and costs of financing needed in the future; changes in equity markets; inflation; fluctuations in commodity prices; delays in the development of projects; the other risks involved in the mineral exploration and development industry; and those risks set out in the Corporation's public documents filed on SEDAR+ at Although the Corporation believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. The Corporation disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news in to access your portfolio
Yahoo
26 minutes ago
- Yahoo
Viking Therapeutics, Inc. (VKTX) Stock Drops Despite Market Gains: Important Facts to Note
Viking Therapeutics, Inc. (VKTX) closed at $28.59 in the latest trading session, marking a -1.26% move from the prior day. The stock's performance was behind the S&P 500's daily gain of 0.38%. On the other hand, the Dow registered a gain of 0.24%, and the technology-centric Nasdaq increased by 0.24%. Prior to today's trading, shares of the company had gained 8.96% outpaced the Medical sector's gain of 4.64% and the S&P 500's gain of 6.6%. The investment community will be paying close attention to the earnings performance of Viking Therapeutics, Inc. in its upcoming release. The company is expected to report EPS of -$0.44, down 120% from the prior-year quarter. Regarding the entire year, the Zacks Consensus Estimates forecast earnings of -$1.86 per share and revenue of $25 million, indicating changes of -84.16% and 0%, respectively, compared to the previous year. Investors should also note any recent changes to analyst estimates for Viking Therapeutics, Inc. Recent revisions tend to reflect the latest near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential. Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system. The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. Right now, Viking Therapeutics, Inc. possesses a Zacks Rank of #3 (Hold). The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 74, which puts it in the top 31% of all 250+ industries. The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Ensure to harness to stay updated with all these stock-shifting metrics, among others, in the next trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Viking Therapeutics, Inc. (VKTX) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Yahoo
27 minutes ago
- Yahoo
IonQ, Inc. (IONQ) Stock Slides as Market Rises: Facts to Know Before You Trade
In the latest close session, IonQ, Inc. (IONQ) was down 2.49% at $38.71. This change lagged the S&P 500's 0.38% gain on the day. At the same time, the Dow added 0.24%, and the tech-heavy Nasdaq gained 0.24%. Prior to today's trading, shares of the company had gained 18.83% outpaced the Computer and Technology sector's gain of 11.61% and the S&P 500's gain of 6.6%. The investment community will be paying close attention to the earnings performance of IonQ, Inc. in its upcoming release. The company's earnings per share (EPS) are projected to be -$0.13, reflecting a 27.78% increase from the same quarter last year. Meanwhile, our latest consensus estimate is calling for revenue of $17.02 million, up 49.56% from the prior-year quarter. For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of -$0.47 per share and a revenue of $85 million, representing changes of +69.87% and +97.34%, respectively, from the prior year. Investors should also note any recent changes to analyst estimates for IonQ, Inc. Recent revisions tend to reflect the latest near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential. Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system. The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. At present, IonQ, Inc. boasts a Zacks Rank of #2 (Buy). The Computer - Integrated Systems industry is part of the Computer and Technology sector. This industry, currently bearing a Zacks Industry Rank of 54, finds itself in the top 22% echelons of all 250+ industries. The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Remember to apply to follow these and more stock-moving metrics during the upcoming trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report IonQ, Inc. (IONQ) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
